TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00453180

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: N-acetylcysteine
Description: Capsules available in 300 mg or 600mg strength. Target dose of n-acetylcysteine will be 60mg/kg/day TID. Dosage will be increased to this target dose from week 1 to week 3 barring side effects. Dose reduction will be allowed at any time for adverse side effects. Maximum dose of n-acetylcysteine will be 4200mg/day.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subjects randomized to placebo arm will receive placebo pill for duration of study.
Study: NCT03424577

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: H3B-6527
Description: Oral capsule
Study: NCT04871581

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: NTI-tss
Description: FDA cleared device for prophylactic treatment of medically diagnosed migraine pain

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Similar to Device, but having no influence on clenching intensity
Study: NCT04248400

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Tai Chi training
Description: A 24 weeks Tai Chi training with three 1-hour section per week

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional exercise
Description: A 24 weeks conventional exercise training with three 1-hour section per week
Study: NCT00812240

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Masitinib

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Masitinib

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Imatinib
Description: imatinib 400 mg or 600 mg per day, per os

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Imatinib
Description: imatinib 400 mg or 600 mg per day, per os
Study: NCT02883777

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: High Protein and Low Glycemic Index Diet
Description: It will be evaluated a type of high protein diet with 1,3g/kg/day in kidney transplant recipients over 1 year after transplantation.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Diet
Description: Conventional diet over 1 year after transplantation.
Study: NCT03713957

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GRF6021
Description: GRF6021 for IV infusion

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo for IV infusion
Study: NCT01926470

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: anteroposterior approach group
Description: anteroposterior approach group (n=104): check intravascular injection while performing S1 transforaminal epidural steroid injection in anteroposterior view under fluoroscopy

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: oblique approach group
Description: oblique approach group (n=104): same as anteroposterior approach group except using oblique view
Study: NCT03629691

Intervention type: OTHER
Intervention: lung cavitation
Description: apatinib treated patients developed lung cavitation

Intervention type: OTHER
Intervention: lung cavitation
Description: apatinib treated patients developed lung cavitation
Study: NCT04409301

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: My Special Aflac Duck (MSAD)
Description: The hospital Child Life Specialist or research team member will introduce the child and parent to My Special Aflac Duck MSAD), with instructions on how to use the duck. MSAD is a robotic toy with an associated app. Children can use MSAD for play, exploring feelings, and describing medical procedures. Intervention hospitals are permitted to provide their standard of care from Child Life with the exception of providing stuffed animal-like objects. Data will be recorded by Child Life or research team member on what tools are used outside of the MSAD.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard of care control
Description: Sites will follow their individual standard of care from Child Life. Data will be recorded by Child Life on what tools are used. After completion of the 3-month survey, patients at hospitals assigned to not initially receive MSAD will each receive a MSAD.
Study: NCT02906956

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Preferred music playlist
Description: Client will be instructed in a home program based on repetitive task practice principles and will complete this program with and without the use of a preferred music playlist during practice.
Study: NCT03039920

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Electronic cigarette
Description: Smoking of electronic cigarette

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional cigarette
Description: Smoking tobacco cigarette
Study: NCT01263093

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clopidogrel

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clopidogrel

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2216684

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2216684
Study: NCT02174861

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erenumab
Description: Administered by subcutaneous injection once a month
Study: NCT00714298

Intervention type: OTHER
Group type: OTHER
Intervention: Measure of Initial heart fatty acid binding protein and ischemia modified albumin
Description: Initial heart fatty acid binding protein and ischemia modified albumin will be measured after patient's arrival in the emergency room. The aim of the study is to analyse the predictive value of association of heart fatty binding protein and ischemia modified albumin for non ST segment elevation acute coronary syndrome diagnosis in the first hour of management in the emergency room.Treating physicians, biologist physician will be blinded to the results of the markers.
Study: NCT04191655

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Dye Spraying Chromocolonoscopy
Description: A colonoscopy that used high definition camera in addition to dye spraying on the interior colon surface.
Study: NCT04093635

Intervention type: DEVICE
Intervention: Negative Pressure Wound Therapy
Description: VAC was applied by placing sterile pads in two layers with a 16Fr Ryle's tube placed between the two layers and then the wound was sealed by a sterile transparent polyurethane sheet. The tube was connected to a wall-mounted suction device and the pressure will be set at -125 mmHg Mode of NPWT. This dressing will be changed every 72 hrs

Intervention type: DEVICE
Intervention: Negative Pressure Wound Therapy
Description: VAC was applied by placing sterile pads in two layers with a 16Fr Ryle's tube placed between the two layers and then the wound was sealed by a sterile transparent polyurethane sheet. The tube was connected to a wall-mounted suction device and the pressure will be set at -125 mmHg Mode of NPWT. This dressing will be changed every 72 hrs
Study: NCT00121316

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pimecrolimus
Description: Pimecrolimus Cream 1 %

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Vehicle cream (placebo cream)
Study: NCT03340142

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: VIVO™
Description: Diagnose the area of a PVC or VT onset
Study: NCT03424512

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Group Metacognitive Therapy
Description: Group MCT is based on a manualised protocol and is structured in the following way. In session 1, idiosyncratic case formulations based on the generic metacognitive model are developed for each participant. Socialization helps patients to understand that worry/rumination and unhelpful coping strategies are maintaining emotional distress. Patients are then introduced to, and practice well established treatment techniques to modify negative beliefs about uncontrollability of rumination/worry. Later sessions address relapse prevention and involves modifying remaining use of the 'cognitive attentional syndrome', reviewing residual conviction in positive and negative beliefs and consolidating and strengthening alternative ways of responding to negative thoughts.
Study: NCT00289757

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Havrix™
Description: 2 doses at 6 months interval
Study: NCT03519659

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: PET/CT scan with 13 mCi radiation dose
Description: 13 mCi 18F-FDG dose

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: PET/CT scan with 13 mCi radiation dose
Description: 13 mCi 18F-FDG dose

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: PET/CT scan with 13 mCi radiation dose
Description: 13 mCi 18F-FDG dose

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: PET/CT scan with 13 mCi radiation dose
Description: 13 mCi 18F-FDG dose

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: PET/CT scan with 13 mCi radiation dose
Description: 13 mCi 18F-FDG dose

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: PET/CT scan with 5 mCi radiation dose
Description: 5 mCi 18F-FDG dose

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: PET/CT scan with 5 mCi radiation dose
Description: 5 mCi 18F-FDG dose

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: PET/CT scan with 5 mCi radiation dose
Description: 5 mCi 18F-FDG dose

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: PET/CT scan with 5 mCi radiation dose
Description: 5 mCi 18F-FDG dose
Study: NCT02685826

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: single use vials administered via intravenous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: single use vials administered via intravenous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: single use vials administered via intravenous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: capsules for oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: capsules for oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: capsules for oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: tablets for oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: tablets for oral administration
Study: NCT04122846

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Emotional Awareness and Expression Therapy
Description: Very much based on Unlearn your pain by Howard Schubiner.
Study: NCT02743767

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Introducing five different treating adaptations
Description: Immediate Bag-valve mask ventilation after administering of muscle relaxants, optimized preoxygenation, introducing of a preinterventional checklist, increased usage of video laryngoscopy and immediate hand alternately if frustrated intubation.
Study: NCT01977742

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Supervised exercise program
Description: Aerobic, strength and flexibility exercises in a supervised exercise program for 8 weeks; after 8 weeks will add a specific sudden rest-exercise training protocol, three times a week. The cardiac vagal index will be measured at every 8 weeks.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Supervised exercise program
Description: Aerobic, strength and flexibility exercises in a supervised exercise program for 8 weeks; after 8 weeks will add a specific sudden rest-exercise training protocol, three times a week. The cardiac vagal index will be measured at every 8 weeks.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Supervised exercise program together with a specific sudden rest-exercise training protocol
Description: Aerobic, strength and flexibility exercises in a supervised exercise program for 8 weeks together with a specific sudden rest-exercise training protocol, three times a week After 8 weeks will discontinue the specific sudden rest-exercise training protocol. The cardiac vagal index will be measured at every 8 weeks.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Supervised exercise program together with a specific sudden rest-exercise training protocol
Description: Aerobic, strength and flexibility exercises in a supervised exercise program for 8 weeks together with a specific sudden rest-exercise training protocol, three times a week After 8 weeks will discontinue the specific sudden rest-exercise training protocol. The cardiac vagal index will be measured at every 8 weeks.
Study: NCT04326556

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Prospective cohort for etiological and prognostic purposes
Description: Subjects benefit from a standardized, comprehensive geriatric evaluation in accordance with the recommendations of good practice during a geriatric consultation. It is completed by a measurement of the gripping force using a dynamometer and a measurement of the respiratory parameters (vital capacity) using a spirometer. The following acts are added to the consultation: the completion of questionnaires, a semi-directed interview focused on the perception of air pollution, the wearing on the chest for one week of an individual mobile physiological signal sensor (DM with CE marking) and the wearing (on the belt or in a bag) for one week of a portable device with two air pollution sensors.
Study: NCT02066519

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical exercise programme using a rowing machine
Description: 3 sessions per week of individualized physical training using a rowing machine during 3 months.
Study: NCT00605722

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bevacizumab (Avastin)
Description: 5 mg/kg iv on day 1 of each 2 week cycle.
Study: NCT04222530

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Linear EUS first
Description: Linear endoscopic ultrasonography followed by magnifying narrow band endoscopy are used to determine the depth of invasion of early rectal cancer.
Study: NCT01466335

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ronacaleret (100mg tablet)
Description: 100mg tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ronacaleret (100mg tablet)
Description: 100mg tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ronacaleret (100mg tablet)
Description: 100mg tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ronacaleret (100mg tablet)
Description: 100mg tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ronacaleret (100mg tablet)
Description: 100mg tablet

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: matching placebo tablet
Study: NCT03519659

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: PET/CT scan with 2.5 mCi radiation dose
Description: 2.5 mCi 18F-FDG dose

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: PET/CT Scan with 6.5 mCi radiation dose
Description: 6.5 mCi 18F-FDG dose

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: PET/CT Scan with not yet determined radiation dose
Description: We plan for the possibility that one of the three-Sub-Studies (A-B) would not demonstrate equivalency, and we would then perform a modified protocol in which the SOC dosing is compared to a lower and higher dose than originally tested.
Study: NCT00459225

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Iron (ferrous sulfate)
Description: The subjects in the iron treatment arm of the study will receive 3 mg/kg of oral/enteral iron solution once a day beginning at the time of discharge until the pre-Glenn screening which is the endpoint of the study. The iron will be dispensed for the subjects upon discharge from the hospital. The subjects randomized to the no iron treatment arm and the patients in Group II of the study will not receive iron upon discharge. However, they may be started on iron therapy in an intent-to-treat anemia by their primary physician in which case this will serve as the endpoint of the study for these participants.
Study: NCT03400072

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Unsupervised APA program
Description: Exercise training program will consist of one supervised demonstration session with the APA professional, thereafter the training will be continued as unsupervised, home-based exercise training sessions.
Study: NCT04222530

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: ME-NBI first
Description: Magnifying narrow band endoscopy followed by linear endoscopic ultrasonography are used to determine the depth of invasion of early rectal cancer.
Study: NCT02314676

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PEG-somatropin
Study: NCT02159625

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Abdominal Compression Elastic Support
Description: The ACES will be used for HD patients who have had IDH episodes in the last month. For these patients, the ACES will impose a compression pressure of 15 mmHg to compress the abdominal section over the last three hours of the HD treatment. This action can increase venous return and hence cardiac output to improve the cardiovascular function of the patient. In this way, the IDH episode may be prevented or reduced in severity. This use is much less cumbersome over the use of IAB in dealing with PDOH. We perform this trial study to show the use ACES is more effective than the Trendelenburg maneuver or the infusion of isotonic saline, for example.
Study: NCT00888225

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Eccentric exercise
Description: Eccentric exercise treatment performed at home with three sets of 15 repetitions daily

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Concentric exercise
Description: Concentric exercise treatment at home with three sets of 15 repetitions daily
Study: NCT03412825

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Egg supplementation
Description: Participants will required to consume 2 eggs per day, 5 days a week (a total of 10 eggs per week).
Study: NCT01983813

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PHCVRS Intervention
Description: A clinical pharmacist at the PHCVRS will follow each participant in the PHCVRS arm for 12 months, including:~1. Contact via email, phone or text every 2-4 weeks~2. Assessment and counseling for medication adherence, side effects, and lifestyle modifications to decrease risk of cardiovascular disease.~3. Collaborative communication with the participant's physician to address gaps in screening or therapy, update medication list, and recommend medication changes.~Each participant in this arm will also have access to an online Personal Health Record that can be used to track medications, diagnosed conditions and laboratory values related to cardiovascular disease risk.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Personal Health Record
Description: Participant will be able to access an online Personal Health Record for tracking medications and diagnosed conditions

Intervention type: OTHER
Group type: OTHER
Intervention: Personal Health Record
Description: Participant will be able to access an online Personal Health Record for tracking medications and diagnosed conditions
Study: NCT00816764

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AGS-8M4
Description: IV Infusion

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AGS-8M4
Description: IV Infusion

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AGS-8M4
Description: IV Infusion

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AGS-8M4
Description: IV Infusion
Study: NCT04388878

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-07054894
Description: Participants will receive oral ascending doses

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will receive matching placebo
Study: NCT04556188

Intervention type: PROCEDURE
Intervention: Cardiac surgery
Study: NCT02443766

Intervention type: OTHER
Intervention: Meditation Retreat
Description: Weeklong retreat which includes meditation and prayer.
Study: NCT00695877

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ad5.ENVA.48 HIV-1 vaccine
Description: Recombinant adenovirus serotype 5 HIV-1 vaccine
Study: NCT02399787

Intervention type: OTHER
Intervention: blastocyst biopsy
Description: Performed on day 5
Study: NCT03549741

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clomiphene Citrate 50mg
Description: oral tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clomiphene Citrate 50mg
Description: oral tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cabergoline Oral Tablet
Description: oral tablets
Study: NCT00605722

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: erlotinib (Tarceva)
Description: 150 mg orally (po) daily.
Study: NCT03549741

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo Oral Tablet
Description: oral tablets
Study: NCT00695877

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ad5.ENVA.48 HIV-1 vaccine
Description: Recombinant adenovirus serotype 5 HIV-1 vaccine

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ad5.ENVA.48 HIV-1 vaccine
Description: Recombinant adenovirus serotype 5 HIV-1 vaccine

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ad5.ENVA.48 HIV-1 vaccine
Description: Recombinant adenovirus serotype 5 HIV-1 vaccine
Study: NCT03813069

Intervention type: OTHER
Group type: OTHER
Intervention: IR3535
Description: The topical repellent IR3535 (3-\[N-butyl-N-acetyl\]-aminopropionic acid ethyl ester) only

Intervention type: OTHER
Group type: OTHER
Intervention: IR3535
Description: The topical repellent IR3535 (3-\[N-butyl-N-acetyl\]-aminopropionic acid ethyl ester) only

Intervention type: OTHER
Group type: OTHER
Intervention: Permethrin lower dose
Description: A fabric scarf, impregnated with the insecticide permethrin (m-Phenoxybenzyl)-cis,trans-3-(2,2-dichlorovinyl)-2,2-dimethylcyclopropanecarboxylate) that has contact irritancy/spatial repellency. Dose appropriate to children of 10-20 kg.

Intervention type: OTHER
Group type: OTHER
Intervention: Permethrin lower dose
Description: A fabric scarf, impregnated with the insecticide permethrin (m-Phenoxybenzyl)-cis,trans-3-(2,2-dichlorovinyl)-2,2-dimethylcyclopropanecarboxylate) that has contact irritancy/spatial repellency. Dose appropriate to children of 10-20 kg.

Intervention type: OTHER
Group type: OTHER
Intervention: Permethrin higher dose
Description: A fabric scarf, impregnated with the insecticide permethrin (m-Phenoxybenzyl)-cis,trans-3-(2,2-dichlorovinyl)-2,2-dimethylcyclopropanecarboxylate) that has contact irritancy/spatial repellency. Dose appropriate to children more than 20 kg.

Intervention type: OTHER
Group type: OTHER
Intervention: Permethrin higher dose
Description: A fabric scarf, impregnated with the insecticide permethrin (m-Phenoxybenzyl)-cis,trans-3-(2,2-dichlorovinyl)-2,2-dimethylcyclopropanecarboxylate) that has contact irritancy/spatial repellency. Dose appropriate to children more than 20 kg.